Phase I/III

CAN017 is a humanized immunoglobulin gamma 1/kappa (IgG1/) monoclonal antibody that targets the human v-erb-b2 oncogene homolog 3 (ERBB3 or HER-3) receptor and inhibits ERBB3 activities. CAN017 has been tested on 35 CDX models and 26 PDX models in preclinical studies for its in vivo efficacy and the correlation between efficacy of CAN017 and the expression level of NRG1. It is proven that NRG1-positive tumors are enriched with statistical significance for responders to CAN017 and that the in vivo efficacy of CAN017 can potentially be predicted by NRG1 expression levels in the tumors. The completed phase I study of CAN017 on various metastatic or advanced solid tumors also showed that CAN017 was well-tolerated with excellent safety data. CANbridge will develop CAN017 first in squamous cell esophageal cancer, the predominant form of esophageal cancer in China. 

CANbridge has obtained the exclusive global license (exclude North America) for the development, manufacture and commercialization of CAN017.

Indication:Esophageal squamous cell carcinoma

Esophageal cancer is cancer arising from the esophagus—the food pipe that runs between the throat and the stomach. Symptoms often include difficulty in swallowing and weight loss. Other symptoms may include pain when swallowing, a hoarse voice, enlarged lymph nodes ("glands") around the collarbone, a dry cough, and possibly coughing up or vomiting blood.

The two main sub-types of the disease are esophageal squamous-cell carcinoma (often abbreviated to ESCC), which is more common in the developing world, and esophageal adenocarcinoma (EAC), which is more common in the developed world. A number of less common types also occur. Squamous-cell carcinoma arises from the epithelial cells that line the esophagus. Adenocarcinoma arises from glandular cells present in the lower third of the esophagus, often where they have already transformed to intestinal cell type (a condition known as Barrett's esophagus). Causes of the squamous-cell type include tobacco, alcohol, very hot drinks, poor diet, and chewing betel nut. The most common causes of the adenocarcinoma type are smoking tobacco, obesity, and acid reflux.

As of 2012, esophageal cancer was the eighth-most common cancer globally with 456,000 new cases during the year. It caused about 400,000 deaths that year, up from 345,000 in 1990. Rates vary widely among countries, with about half of all cases occurring in China. It is around three times more common in men than in women. Outcomes are related to the extent of the disease and other medical conditions, but generally tend to be fairly poor, as diagnosis is often late. Five-year survival rates are around 13% to 18%.